In a research report released Tuesday, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Sophiris Bio Inc (NASDAQ:SPHS), but reduced his price …
Maxim Group analyst Jason Kolbert maintained a Buy rating on Sophiris Bio Inc (NASDAQ:SPHS) with a price target of $10, which represents a …
